BioNexus Gene Lab (BGLC) Current Assets (2018 - 2026)

BioNexus Gene Lab has disclosed Current Assets across 9 years of filings, most recently posting $4.9 million for Q2 2026.

• In Q2 2026, Current Assets fell 22.51% year-over-year to $4.9 million; the TTM figure through Jun 2026 stood at $4.9 million (down 22.51% YoY), while the FY2025 annual figure was $5.4 million, down 26.67% from the prior year.
• Current Assets came in at $4.9 million for Q2 2026 at BioNexus Gene Lab, down from $5.2 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $8.3 million in Q3 2023 to a low of $4.9 million in Q2 2026.
• Average Current Assets over 5 years is $6.4 million, with a median of $6.2 million recorded in 2022.
• Year-over-year, Current Assets decreased 26.93% in 2022 and surged 52.89% in 2023.
• Over 5 years, Current Assets stood at $6.0 million in 2022, then soared by 33.63% to $8.0 million in 2023, then declined by 7.66% to $7.4 million in 2024, then dropped by 26.67% to $5.4 million in 2025, then fell by 9.27% to $4.9 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $4.9 million in Q2 2026, $5.2 million in Q1 2026, and $5.4 million in Q4 2025.